|
|
Article: Altus Pharmaceuticals Announces Completion of Clinical Testing in the Phase I Study of ALTU-238 - a Long-Acting Crystalline Formulation of Human Growth Hormone.
- Article from:
- Business Wire
- Article date:
- June 6, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CAMBRIDGE, Mass. -- Plans to Initiate Phase II Multi-Center Trial in Adults with Growth Hormone Deficiency
Altus(R) Pharmaceuticals Inc., a leader in the development of novel protein therapies to treat chronic gastrointestinal and metabolic diseases, announced today that it has successfully completed clinical testing in the Phase I study for ALTU-238, a long-acting crystalline formulation of recombinant human growth hormone (somatropin). The study was designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of ALTU-238 in normal healthy volunteers. The Company also announced it plans to initiate a multi-center Phase ...